Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective diligently but unsuccessfully to develop a single therapy, variously called Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are actually building up, whether they will actually be being used is an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as a combination therapy in the therapy of multi-drug-resistant HIV have been closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my last several shares. My 1st CytoDyn post, “CytoDyn: What To Do When It’s Too Good To Be True?”, set out what follows prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan presented such a highly promotional image in the Uptick Newswire interview which I came away with an inadequate viewpoint of the company.

Irony of irony, the poor viewpoint of mine of the business has grown steadily, yet the disappointment hasn’t been financial. Two many years ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades during $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is it that delivers a > 6 bagger at the moment still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied therapy (which I shall relate to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor of the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti viral activity in HIV infected subjects. Today’s transaction of $3.5 zillion transfers ownership of the expertise as well as linked intellectual property coming from Progenics to CytoDyn, as well as roughly twenty five million mg of bulk drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and the first brand new drug application approval ($five million), as well as royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to acquire a market cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Rather than having a pipeline with many therapies and many indications, it’s this single treatments and a “broad pipeline of indications” since it places it. I call certain pipelines, “pipedots.” In CytoDyn’s situation it touts the leronlimab of its as a potentially beneficial therapy of dozens of indications.

Its opening banner on the site of its (below) shows an energetic organization with diverse interests albeit centered on leronlimab, several illness types, multiple publications and multiple presentations.

Could all of it be smoke and mirrors? That is a question I’ve been asking myself with the very start of the interest of mine in this organization. Judging by way of the multiples of thousands of several comments on listings accessible through Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some might say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *